BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698. [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077] [Cited by in Crossref: 233] [Cited by in F6Publishing: 228] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
2 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 819] [Article Influence: 72.6] [Reference Citation Analysis]
3 Tsuchiya H, Ashla AA, Hoshikawa Y, Matsumi Y, Kanki K, Enjoji M, Momosaki S, Nakamuta M, Taketomi A, Maehara Y, Shomori K, Kurimasa A, Hisatome I, Ito H, Shiota G. Iron state in association with retinoid metabolism in non-alcoholic fatty liver disease: Iron metabolism in NAFLD. Hepatology Research 2010;40:1227-38. [DOI: 10.1111/j.1872-034x.2010.00719.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
4 Rius B, Titos E, Morán‐salvador E, López‐vicario C, García‐alonso V, González‐périz A, Arroyo V, Claria J. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity‐induced steatohepatitis. FASEB j 2013;28:836-48. [DOI: 10.1096/fj.13-235614] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
5 Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-1067. [PMID: 19846234 DOI: 10.1016/j.jhep.2009.09.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Fujimoto M, Tsuneyama K, Kinoshita H, Goto H, Takano Y, Selmi C, Keen CL, Gershwin ME, Shimada Y. The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. Ann N Y Acad Sci. 2010;1190:151-158. [PMID: 20388146 DOI: 10.1111/j.1749-6632.2009.05265.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
7 Hens W, Vissers D, Hansen D, Peeters S, Gielen J, Van Gaal L, Taeymans J. The effect of diet or exercise on ectopic adiposity in children and adolescents with obesity: a systematic review and meta-analysis. Obes Rev 2017;18:1310-22. [PMID: 28913977 DOI: 10.1111/obr.12577] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
8 Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674-679. [PMID: 19195629 DOI: 10.1016/s1262-3636(08)74603-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Cheng X, Yamauchi J, Lee S, Zhang T, Gong Z, Muzumdar R, Qu S, Dong HH. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. J Biol Chem. 2017;292:3692-3705. [PMID: 28115523 DOI: 10.1074/jbc.m116.765917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Matono T, Koda M, Tokunaga S, Kato J, Sugihara T, Ueki M, Murawaki Y. Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice. Hepatol Res. 2011;41:1240-1248. [PMID: 21951423 DOI: 10.1111/j.1872-034x.2011.00888.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
11 Makris KC, Andrianou XD, Charisiadis P, Burch JB, Seth RK, Ioannou A, Picolos M, Christophi CA, Chatterjee S. Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus. Environment International 2016;92-93:486-93. [DOI: 10.1016/j.envint.2016.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS One 2021;16:e0252164. [PMID: 34081733 DOI: 10.1371/journal.pone.0252164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Choi W, Lee J, Yoon J, Kwak C, Lee YJ, Cho YY, Lee YB, Yu SJ, Kim YJ, Kim HH, Kim H, Cho SY, Lee SB, Jeong H, Kim CY, Lee H. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocrine-Related Cancer 2014;21:343-53. [DOI: 10.1530/erc-14-0036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
14 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Chun YS, Laurent A, Maru D, Vauthey J. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. The Lancet Oncology 2009;10:278-86. [DOI: 10.1016/s1470-2045(09)70064-6] [Cited by in Crossref: 107] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
16 Korkmaz H, Unler GK, Gokturk HS, Schmidt WE, Kebapcilar L. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test: . European Journal of Gastroenterology & Hepatology 2015;27:1137-43. [DOI: 10.1097/meg.0000000000000407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602. [PMID: 20222092 DOI: 10.1002/hep.23567] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 20.8] [Reference Citation Analysis]
18 Dean JT, Rizk ML, Tan Y, Dipple KM, Liao JC. Ensemble modeling of hepatic fatty acid metabolism with a synthetic glyoxylate shunt. Biophys J 2010;98:1385-95. [PMID: 20409457 DOI: 10.1016/j.bpj.2009.12.4308] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
19 Abreu IC, Guerra JF, Pereira RR, Silva M, Lima WG, Silva ME, Pedrosa ML. Hypercholesterolemic diet induces hepatic steatosis and alterations in mRNA expression of NADPH oxidase in rat livers. Arq Bras Endocrinol Metabol 2014;58:251-9. [PMID: 24863087 DOI: 10.1590/0004-2730000002831] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
20 Kocabay G, Karabay CY, Colak Y, Oduncu V, Kalayci A, Akgun T, Guler A, Kirma C. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study. Clin Sci (Lond). 2014;126:297-304. [PMID: 23947743 DOI: 10.1042/cs20130298] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
21 Arinc H, Sarli B, Baktir AO, Saglam H, Demirci E, Dogan Y, Kurtul S, Karaman H, Erden A, Karaman A. Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis. Ups J Med Sci. 2013;118:228-234. [PMID: 23829707 DOI: 10.3109/03009734.2013.814734] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
22 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 2012;103:1-64. [DOI: 10.1016/s0001-7310(12)70001-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
23 Wang Y, Wang H, Deng P, Tao T, Liu H, Wu S, Chen W, Qin J. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System. ACS Biomater Sci Eng 2020;6:5734-43. [DOI: 10.1021/acsbiomaterials.0c00682] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
24 Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, Lee W, Cho BR, Kim YH, Lee BK, Ryu DR, Lee JW. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol 2013; 19(38): 6453-6457 [PMID: 24151364 DOI: 10.3748/wjg.v19.i38.6453] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
25 Yilmaz Y, Eren F. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clin Chim Acta 2012;414:154-7. [PMID: 22985537 DOI: 10.1016/j.cca.2012.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
26 Seyedian SS, Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Alavinejad P, Hormati A, Javaherforoushzadeh A, Khabazkhoob M. Relationship between serum ferritin level and transient elastography findings among patients with nonalcoholic fatty liver disease. J Family Med Prim Care 2017;6:750-4. [PMID: 29564257 DOI: 10.4103/jfmpc.jfmpc_158_17] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care 2008;11:766-73. [PMID: 18827582 DOI: 10.1097/MCO.0b013e328312c353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
28 Rensen SS, Slaats Y, Driessen A, Peutz-Kootstra CJ, Nijhuis J, Steffensen R, Greve JW, Buurman WA. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology. 2009;50:1809-1817. [PMID: 19821522 DOI: 10.1002/hep.23228] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 6.4] [Reference Citation Analysis]
29 Vizzutti; F, Arena; U, Nobili; V, Tarquini; R, Trappoliere; M, Laffi; G, Marra; F, Pinzani M. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology 2009;8:89-94. [DOI: 10.1016/s1665-2681(19)31784-3] [Cited by in Crossref: 30] [Article Influence: 2.3] [Reference Citation Analysis]
30 Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9. [DOI: 10.1007/s12072-015-9679-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
31 Kitajima Y, Hyogo H, Sumida Y, Eguchi Y, Ono N, Kuwashiro T, Tanaka K, Takahashi H, Mizuta T, Ozaki I, Eguchi T, Kimura Y, Fujimoto K, Anzai K; Japan Nonalcoholic Fatty Liver Disease Study Group (JSG-NAFLD). Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol. 2013;28:1507-1514. [PMID: 23577962 DOI: 10.1111/jgh.12227] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
32 Gao B. Innate immunity and steatohepatitis: a critical role of another toll (TLR-9). Gastroenterology. 2010;139:27-30. [PMID: 20639084 DOI: 10.1053/j.gastro.2010.05.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
33 Osaki A, Kubota T, Suda T, Igarashi M, Nagasaki K, Tsuchiya A, Yano M, Tamura Y, Takamura M, Kawai H, Yamagiwa S, Kikuchi T, Nomoto M, Aoyagi Y. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World J Gastroenterol 2010; 16(23): 2918-2925 [PMID: 20556839 DOI: 10.3748/wjg.v16.i23.2918] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
34 Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380-388. [PMID: 19501927 DOI: 10.1016/j.jhep.2009.03.025] [Cited by in Crossref: 188] [Cited by in F6Publishing: 182] [Article Influence: 14.5] [Reference Citation Analysis]
35 Kawamura Y, Arase Y, Ikeda K, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Inao M, Mochida S, Kumada H. Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. Clin Gastroenterol Hepatol 2016;14:597-605. [PMID: 26707683 DOI: 10.1016/j.cgh.2015.11.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
36 Egan CE, Daugherity EK, Rogers AB, Abi Abdallah DS, Denkers EY, Maurer KJ. CCR2 and CD44 promote inflammatory cell recruitment during fatty liver formation in a lithogenic diet fed mouse model. PLoS One 2013;8:e65247. [PMID: 23762326 DOI: 10.1371/journal.pone.0065247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
37 Moradi MN, Behrouj H, Alipoor B, Kheiripour N, Ghasemi H, Ghasemi H. Chlorella vulgaris is an effective supplement in counteracting non-alcoholic fatty liver disease-related complications through modulation of dyslipidemia, insulin resistance, and inflammatory pathways. J Food Biochem 2021;45:e13914. [PMID: 34459004 DOI: 10.1111/jfbc.13914] [Reference Citation Analysis]
38 Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42:264-272. [PMID: 22175908 DOI: 10.1111/j.1872-034x.2011.00915.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
39 Bruguera M. Practical guidelines for examination of adults with asymptomatic hypertransaminasaemia. Gastroenterología y Hepatología (English Edition) 2017;40:99-106. [DOI: 10.1016/j.gastre.2016.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Linhart KB, Glassen K, Peccerella T, Waldherr R, Linhart H, Bartsch H, Seitz HK. The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2015;4:117-23. [PMID: 26005678 DOI: 10.3978/j.issn.2304-3881.2015.01.14] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
41 Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9. [PMID: 19827166 DOI: 10.1002/hep.23276] [Cited by in Crossref: 737] [Cited by in F6Publishing: 661] [Article Influence: 61.4] [Reference Citation Analysis]
42 Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, Leclercq IA. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2010;298:G107-G116. [PMID: 19875703 DOI: 10.1152/ajpgi.00391.2009] [Cited by in Crossref: 149] [Cited by in F6Publishing: 144] [Article Influence: 11.5] [Reference Citation Analysis]
43 Castéra L, Foucher J, Bernard P, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. Hepatology 2010. [DOI: 10.1002/hep.23425] [Cited by in Crossref: 141] [Cited by in F6Publishing: 322] [Article Influence: 11.8] [Reference Citation Analysis]
44 Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-1067. [PMID: 19846234 DOI: 10.1016/j.jhep.2009.09.001] [Cited by in Crossref: 304] [Cited by in F6Publishing: 289] [Article Influence: 23.4] [Reference Citation Analysis]
45 Manoria P, Inamdar S, Kumar R. Hepatobiliary dysfunction in Type-2 diabetes mellitus. J Family Med Prim Care 2017;6:563-7. [PMID: 29417009 DOI: 10.4103/2249-4863.222018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Birjandi M, Ayatollahi SM, Pourahmad S, Safarpour AR. Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J 2016;18:e32858. [PMID: 28191344 DOI: 10.5812/ircmj.32858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
47 Bruguera M. Practical guidelines for examination of adults with asymptomatic hypertransaminasaemia. Gastroenterol Hepatol 2017;40:99-106. [PMID: 27140949 DOI: 10.1016/j.gastrohep.2016.03.001] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:833-49. [PMID: 25099546 DOI: 10.3945/ajcn.114.086314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 15.8] [Reference Citation Analysis]
49 Wierzbicki AS, Pendleton S, McMahon Z, Dar A, Oben J, Crook MA, Botha AJ. Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Int J Clin Pract. 2011;65:713-715. [PMID: 21564446 DOI: 10.1111/j.1742-1241.2011.02683.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
50 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
51 Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. Hepatol Int 2013;7:850-8. [DOI: 10.1007/s12072-012-9419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
52 Da Silva Morais A, Lebrun V, Abarca-Quinones J, Brichard S, Hue L, Guigas B, Viollet B, Leclercq IA. Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation. J Hepatol 2009;50:489-500. [PMID: 19155087 DOI: 10.1016/j.jhep.2008.10.027] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
53 Wanninger J, Neumeier M, Weigert J, Bauer S, Weiss TS, Schäffler A, Krempl C, Bleyl C, Aslanidis C, Schölmerich J. Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol. 2009;297:G611-G618. [PMID: 19608729 DOI: 10.1152/ajpgi.90644.2008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
54 Aldámiz-echevarría L, de las Heras J, Couce ML, Alcalde C, Vitoria I, Bueno M, Blasco-alonso J, Concepción García M, Ruiz M, Suárez R, Andrade F, Villate O. Non-alcoholic fatty liver in hereditary fructose intolerance. Clinical Nutrition 2020;39:455-9. [DOI: 10.1016/j.clnu.2019.02.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
55 Öner-iyidoğan Y, Tanrıkulu-küçük S, Seyithanoğlu M, Koçak H, Doğru-abbasoğlu S, Aydın AF, Beyhan-özdaş Ş, Yapışlar H, Koçak-toker N. Effect of curcumin on hepatic heme oxygenase 1 expression in high fat diet fed rats: is there a triangular relationship? Can J Physiol Pharmacol 2014;92:805-12. [DOI: 10.1139/cjpp-2014-0174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
56 Yang HR. Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease. Korean J Pediatr 2013;56:45-51. [PMID: 23482433 DOI: 10.3345/kjp.2013.56.2.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
57 Trovato GM, Martines GF, Garozzo A, Tonzuso A, Timpanaro R, Pirri C, Trovato FM, Catalano D. Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int. 2010;30:184-190. [PMID: 19840251 DOI: 10.1111/j.1478-3231.2009.02127.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
58 Fazeli Dehkordy S, Fowler KJ, Mamidipalli A, Wolfson T, Hong CW, Covarrubias Y, Hooker JC, Sy EZ, Schlein AN, Cui JY, Gamst AC, Hamilton G, Reeder SB, Sirlin CB. Hepatic steatosis and reduction in steatosis following bariatric weight loss surgery differs between segments and lobes. Eur Radiol 2019;29:2474-80. [PMID: 30547206 DOI: 10.1007/s00330-018-5894-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
60 Vizzutti F, Provenzano A, Galastri S, Milani S, Delogu W, Novo E, Caligiuri A, Zamara E, Arena U, Laffi G. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest. 2010;90:104-115. [PMID: 19901911 DOI: 10.1038/labinvest.2009.112] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
61 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
62 Riley P, Al Bakir M, O’donohue J, Crook M. Prescribing Statins to Patients with Nonalcoholic Fatty Liver Disease: Real Cardiovascular Benefits Outweigh Theoretical Hepatotoxic Risk. Cardiovascular Therapeutics 2009;27:216-20. [DOI: 10.1111/j.1755-5922.2009.00088.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
63 Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clin Mol Hepatol 2020;26:728-35. [PMID: 33053942 DOI: 10.3350/cmh.2020.0202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
65 Jeon D, Son M, Shim J. Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status. Nutrients 2021;13:1720. [PMID: 34069568 DOI: 10.3390/nu13051720] [Reference Citation Analysis]
66 Niu GC, Liu L, Zhang XL. Hepatobiliary complications of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2012; 20(8): 662-669 [DOI: 10.11569/wcjd.v20.i8.662] [Reference Citation Analysis]
67 Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY;  Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011;12:38-44. [PMID: 21276207 DOI: 10.1111/j.1751-2980.2010.00476.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 155] [Article Influence: 13.5] [Reference Citation Analysis]
68 Acharya UR, Faust O, Molinari F, Sree SV, Junnarkar SP, Sudarshan V. Ultrasound-based tissue characterization and classification of fatty liver disease: A screening and diagnostic paradigm. Knowledge-Based Systems 2015;75:66-77. [DOI: 10.1016/j.knosys.2014.11.021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
69 Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol 2014; 6(7): 496-503 [PMID: 25068001 DOI: 10.4254/wjh.v6.i7.496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
70 Cordero-Pérez P, Torres-González L, Aguirre-Garza M, Camara-Lemarroy C, Guzmán-de la Garza F, Alarcón-Galván G, Zapata-Chavira H, de Jesús Sotelo-Gallegos M, Nadjedja Torres-Esquivel C, Sánchez-Fresno E, Cantú-Sepúlveda D, González-Saldivar G, Bernal-Ramirez J, E Muñoz-Espinosa L. Hepatoprotective effect of commercial herbal extracts on carbon tetrachloride-induced liver damage in Wistar rats. Pharmacognosy Res 2013;5:150-6. [PMID: 23900881 DOI: 10.4103/0974-8490.112417] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
71 Yang Y, Zhang W, Wu X, Wu J, Sun C, Luo F, Pei Z. Systemic Overexpression of GDF5 in Adipocytes but Not Hepatocytes Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver in Mice. Can J Gastroenterol Hepatol 2021;2021:8894685. [PMID: 33542911 DOI: 10.1155/2021/8894685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Constantinescu C, SĂndulescu L, SĂftoiu A. The Role of Elastography in Non-Alcoholic Fatty Liver Disease. Curr Health Sci J 2020;46:255-69. [PMID: 33304627 DOI: 10.12865/CHSJ.46.03.07] [Reference Citation Analysis]
73 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol 2014; 6(5): 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
74 Schelbert KB. Comorbidities of obesity. Prim Care 2009;36:271-85. [PMID: 19501243 DOI: 10.1016/j.pop.2009.01.009] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 6.4] [Reference Citation Analysis]
75 Mahmoud AM, Ding X, Dutta D, Singh VP, Kim K. Detecting hepatic steatosis using ultrasound-induced thermal strain imaging: an ex vivo animal study. Phys Med Biol 2014;59:881-95. [PMID: 24487698 DOI: 10.1088/0031-9155/59/4/881] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
76 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J. Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2012;103:1-64. [DOI: 10.1016/s1578-2190(12)70829-6] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
77 Ochi H, Hirooka M, Koizumi Y, Miyake T, Tokumoto Y, Soga Y, Tada F, Abe M, Hiasa Y, Onji M. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012;56:1271-8. [PMID: 22488593 DOI: 10.1002/hep.25756] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 7.5] [Reference Citation Analysis]
78 Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2011;58:1375-1392, x. [PMID: 22093857 DOI: 10.1016/j.pcl.2011.09.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
79 Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol. 2010;26:39-46. [PMID: 20001571 DOI: 10.3109/09513590903184084] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
80 Chen Y, Mu P, He S, Tang X, Guo X, Li H, Xu H, Woo SL, Qian X, Zeng L. Gly482Ser mutation impairs the effects of peroxisome proliferator-activated receptor γ coactivator-1α on decreasing fat deposition and stimulating phosphoenolpyruvate carboxykinase expression in hepatocytes. Nutr Res. 2013;33:332-339. [PMID: 23602251 DOI: 10.1016/j.nutres.2013.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
81 Iritani S, Akuta N, Kawamura Y, Kajiwara A, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saito S, Suzuki F, Arase Y, Ikeda K, Suzuki Y, Kumada H. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol 2020;20:368. [PMID: 33148171 DOI: 10.1186/s12876-020-01509-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Kawaguchi T, Shiba N, Maeda T, Matsugaki T, Takano Y, Itou M, Sakata M, Taniguchi E, Nagata K, Sata M. Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: a pilot study. J Gastroenterol. 2011;46:746-757. [PMID: 21340530 DOI: 10.1007/s00535-011-0378-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
83 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
84 Li D, Zheng J, Hu Y, Hou H, Hao S, Liu N, Wang Y. Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats. Pharmacogn Mag 2017;13:677-82. [PMID: 29200733 DOI: 10.4103/pm.pm_584_16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
85 Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Murakami Y. Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases. Biomarkers 2013;18:82-7. [PMID: 23136827 DOI: 10.3109/1354750X.2012.738249] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
86 Petta S, Marchesini G, Caracausi L, Macaluso FS, Cammà C, Ciminnisi S, Cabibi D, Porcasi R, Craxì A, Di Marco V. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Hepatol 2013;59:1169-76. [PMID: 23933265 DOI: 10.1016/j.jhep.2013.07.037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
87 Oh S, Maruyama T, Eguchi K, Shida T, Arai E, Isobe T, Okamoto Y, Shoda J. Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: a pilot trial. Ther Clin Risk Manag 2015;11:371-80. [PMID: 25767392 DOI: 10.2147/TCRM.S75109] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
88 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 2020;245:96-108. [PMID: 31924111 DOI: 10.1177/1535370219898141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
89 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013;4:51-63. [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 77] [Article Influence: 10.9] [Reference Citation Analysis]
90 Tan XP, Zhou K, Zeng QL, Yuan YF, Chen W. Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 35293607 DOI: 10.1007/s10238-022-00813-4] [Reference Citation Analysis]
91 Hendrikx T, Walenbergh SM, Jeurissen ML, Houben T, van Gorp PJ, Lindsey PJ, Koek GH, Kalhan S, Pihlajamaki J, Hofker MH, Shiri-sverdlov R. Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis. Biomarkers in Medicine 2015;9:1301-9. [DOI: 10.2217/bmm.15.71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
92 Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, Tokushige K, Hashimoto E, Utsunomiya H, Takahashi H, Ishii T. Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J Gastroenterol. 2013;48:620-632. [PMID: 22972520 DOI: 10.1007/s00535-012-0659-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
93 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
94 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 2016;16:141. [PMID: 27955628 DOI: 10.1186/s12876-016-0557-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
95 Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Emerging drugs for non-alcoholic steatohepatitis. Expert Opin Emerg Drugs. 2013;18:279-290. [PMID: 23848366 DOI: 10.1517/14728214.2013.811232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
96 Soleimani D, Paknahad Z, Askari G, Iraj B, Feizi A. Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Adv Biomed Res. 2016;5:2. [PMID: 26955623 DOI: 10.4103/2277-9175.174962] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
97 Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132. [PMID: 22126026 DOI: 10.1016/b978-0-12-387042-1.00006-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
98 Tan H, Chang JP. Non-Alcoholic Fatty Liver Disease. Proceedings of Singapore Healthcare 2010;19:36-50. [DOI: 10.1177/201010581001900106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
99 Chien Y, Tsai P, Lai Y, Lu K, Liu C, Lin H, Huang C, Wu W, Wang C. CircularRNA as novel biomarkers in liver diseases. Journal of the Chinese Medical Association 2020;83:15-7. [DOI: 10.1097/jcma.0000000000000230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
100 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
101 Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T. Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan. BMC Res Notes. 2011;4:341. [PMID: 21906297 DOI: 10.1186/1756-0500-4-341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
102 Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, Kozlov AV, Haindl S, Kenner L, Kolbe T, Mueller M, Snibson KJ, Heim MH, Moriggl R. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology 2012;55:941-52. [PMID: 22031092 DOI: 10.1002/hep.24765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
103 Colak Y, Ozturk O, Senates E, Tuncer I, Yorulmaz E, Adali G, Doganay L, Enc FY. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit. 2011;17:HY5-HY9. [PMID: 21525818 DOI: 10.12659/msm.881749] [Cited by in Crossref: 86] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
104 Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5:406-415. [PMID: 23560695 DOI: 10.1111/1753-0407.12056] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
105 Castera L. Quels outils pour le diagnostic non invasif de la stéatose et de la fibrose chez les patients atteints de stéatopathie métabolique ? Gastroentérologie Clinique et Biologique 2009;33:405-12. [DOI: 10.1016/j.gcb.2009.02.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Ebrahimi-Mameghani M, Aliashrafi S, Javadzadeh Y, AsghariJafarabadi M. The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease. Health Promot Perspect 2014;4:107-15. [PMID: 25097844 DOI: 10.5681/hpp.2014.014] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
107 Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 2011;1807:664-78. [PMID: 21111705 DOI: 10.1016/j.bbabio.2010.11.004] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
108 Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013;92:114-118. [PMID: 23159641 DOI: 10.1016/j.lfs.2012.11.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
109 Promrat K, Longato L, Wands JR, de la Monte SM. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res 2011;41:754-62. [PMID: 21794038 DOI: 10.1111/j.1872-034X.2011.00815.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
110 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
111 Shavakhi A, Torki M, Khodadoostan M, Shavakhi S. Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. Adv Biomed Res 2015;4:212. [PMID: 26605241 DOI: 10.4103/2277-9175.166149] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Ebrahimi-mameghani M, Sadeghi Z, Abbasalizad Farhangi M, Vaghef-mehrabany E, Aliashrafi S. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris : A double-blind placebo-controlled randomized clinical trial. Clinical Nutrition 2017;36:1001-6. [DOI: 10.1016/j.clnu.2016.07.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
113 Kawamura Y, Ikeda K, Arase Y, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Intern Med 2017;56:1459-65. [PMID: 28626169 DOI: 10.2169/internalmedicine.56.7830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
114 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
116 Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, Hasselblatt P, Schlederer M, Haindl S, Wagner KU, Engblom D, Haemmerle G, Kratky D, Sexl V, Kenner L, Kozlov AV, Terracciano L, Zechner R, Schuetz G, Casanova E, Pospisilik JA, Heim MH, Moriggl R. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 2011;54:1398-409. [PMID: 21725989 DOI: 10.1002/hep.24509] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 6.7] [Reference Citation Analysis]
117 Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365-383. [PMID: 20415685 DOI: 10.1111/j.1463-1326.2009.01176.x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 138] [Article Influence: 12.9] [Reference Citation Analysis]
118 Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012;39:374-383. [PMID: 22846856 DOI: 10.1053/j.seminoncol.2012.05.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
119 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. BMC Gastroenterol 2021;21:434. [PMID: 34798835 DOI: 10.1186/s12876-021-02020-z] [Reference Citation Analysis]
120 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
121 Lee L, Alloosh M, Saxena R, Van Alstine W, Watkins BA, Klaunig JE, Sturek M, Chalasani N. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology 2009;50:56-67. [PMID: 19434740 DOI: 10.1002/hep.22904] [Cited by in Crossref: 133] [Cited by in F6Publishing: 134] [Article Influence: 10.2] [Reference Citation Analysis]
122 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD. Hepatol Commun 2020;4:66-76. [PMID: 31909356 DOI: 10.1002/hep4.1445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Salman A, Hegazy M, AbdElfadl S. Combined Adiponectin Deficiency and Resistance in Obese Patients: Can It Solve Part of the Puzzle in Nonalcoholic Steatohepatitis. Open Access Maced J Med Sci. 2015;3:298-302. [PMID: 27275239 DOI: 10.3889/oamjms.2015.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
124 Toth PP, Catapano A, Tomassini JE, Tershakovec AM. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology 2010;5:655-84. [DOI: 10.2217/clp.10.49] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
125 Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:76-82. [PMID: 22059453 DOI: 10.1111/j.1365-2036.2011.04916.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 8.6] [Reference Citation Analysis]
126 Kaser S, Ebenbichler CF, Tilg H. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease: Treatment of NAFLD. International Journal of Clinical Practice 2010;64:968-83. [DOI: 10.1111/j.1742-1241.2009.02327.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
127 Kumei S, Yuhki KI, Kojima F, Kashiwagi H, Imamichi Y, Okumura T, Narumiya S, Ushikubi F. Prostaglandin I2 suppresses the development of diet-induced nonalcoholic steatohepatitis in mice. FASEB J 2018;32:2354-65. [PMID: 29247122 DOI: 10.1096/fj.201700590R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
128 Fan J, Farrell GC; the Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in nonviral-related liver diseases. Journal of Gastroenterology and Hepatology 2009;24:712-9. [DOI: 10.1111/j.1440-1746.2009.05776.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
129 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 372] [Cited by in F6Publishing: 347] [Article Influence: 28.6] [Reference Citation Analysis]
130 Zelle DM, Corpeleijn E, van Ree RM, Stolk RP, van der Veer E, Gans RO, Homan van der Heide JJ, Navis G, Bakker SJ. Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients. Am J Transplant. 2010;10:106-114. [PMID: 19951280 DOI: 10.1111/j.1600-6143.2009.02876.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
131 Kälsch J, Bechmann LP, Heider D, Best J, Manka P, Kälsch H, Sowa JP, Moebus S, Slomiany U, Jöckel KH, Erbel R, Gerken G, Canbay A. Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 2015;5:13058. [PMID: 26269425 DOI: 10.1038/srep13058] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
132 Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009; 15(35): 4387-4391 [PMID: 19764089 DOI: 10.3748/wjg.15.4387] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
133 Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, Karcz-Socha I, Hopt UT, Bukhari W, Grueneberger JM. Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. J Obes 2011;2011:765473. [PMID: 21274277 DOI: 10.1155/2011/765473] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
134 Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-62. [DOI: 10.1002/hep.23312] [Cited by in Crossref: 720] [Cited by in F6Publishing: 644] [Article Influence: 55.4] [Reference Citation Analysis]
135 Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, Morteza A, Nakhjavani M. Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr. 2010;2:65. [PMID: 21047423 DOI: 10.1186/1758-5996-2-65] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
136 Tallino S, Duffy M, Ralle M, Cortés MP, Latorre M, Burkhead JL. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease. J Nutr Biochem 2015;26:996-1006. [PMID: 26033743 DOI: 10.1016/j.jnutbio.2015.04.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
137 Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19:1313-1323. [PMID: 19693638 DOI: 10.1007/s11695-009-9912-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
138 Ju L, Sun Y, Xue H, Chen L, Gu C, Shao J, Lu R, Luo X, Wei J, Ma X, Bian Z. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis. Sci Rep 2020;10:3201. [PMID: 32081971 DOI: 10.1038/s41598-020-60138-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
139 Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol. 2009;44:1064-1070. [PMID: 19533014 DOI: 10.1007/s00535-009-0091-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
140 Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253-261. [PMID: 22008893 DOI: 10.1038/ajg.2011.327] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 13.5] [Reference Citation Analysis]
141 Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol. 2009;41:969-976. [PMID: 19027869 DOI: 10.1016/j.biocel.2008.10.027] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
142 Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemasa K, Yasui K, Minami M, Imai S, Itoh Y. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients: ALT in NASH progression. Hepatol Res 2015;45:E53-61. [DOI: 10.1111/hepr.12456] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
143 Ashla AA, Hoshikawa Y, Tsuchiya H, Hashiguchi K, Enjoji M, Nakamuta M, Taketomi A, Maehara Y, Shomori K, Kurimasa A, Hisatome I, Ito H, Shiota G. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010;40:594-604. [PMID: 20618457 DOI: 10.1111/j.1872-034X.2010.00646.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
144 Pisonero-Vaquero S, Martínez-Ferreras Á, García-Mediavilla MV, Martínez-Flórez S, Fernández A, Benet M, Olcoz JL, Jover R, González-Gallego J, Sánchez-Campos S. Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease. Mol Nutr Food Res. 2015;59:879-893. [PMID: 25712622 DOI: 10.1002/mnfr.201400913] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
145 Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep 2022. [PMID: 35142988 DOI: 10.1007/s11894-022-00835-8] [Reference Citation Analysis]
146 Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol 2018;18:165. [PMID: 30400829 DOI: 10.1186/s12876-018-0900-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
147 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
148 Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010;33:1134-9. [PMID: 20185740 DOI: 10.2337/dc09-1765] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 10.1] [Reference Citation Analysis]
149 Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, Schmittgen TD, Croce C, Ghoshal K, Jacob ST. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology. 2009;50:1152-1161. [PMID: 19711427 DOI: 10.1002/hep.23100] [Cited by in Crossref: 221] [Cited by in F6Publishing: 223] [Article Influence: 17.0] [Reference Citation Analysis]
150 Magini G, Farsad M, Frigerio M, Serra C, Colecchia A, Jovine E, Vivarelli M, Feletti V, Golfieri R, Patti C. C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med. 2009;34:659-665. [PMID: 19893396 DOI: 10.1097/rlu.0b013e3181b53488] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
151 Öner-İyidoğan Y, Koçak H, Seyidhanoğlu M, Gürdöl F, Gülçubuk A, Yildirim F, Çevik A, Uysal M. Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet. J Physiol Biochem 2013;69:677-86. [PMID: 23430567 DOI: 10.1007/s13105-013-0244-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
152 Jiang D. Care of chronic liver disease. Prim Care 2011;38:483-98; viii-ix. [PMID: 21872093 DOI: 10.1016/j.pop.2011.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Chen LW, Chien CH, Kuo SF, Yu CY, Lin CL, Chien RN. Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study. BMC Gastroenterol 2019;19:126. [PMID: 31311491 DOI: 10.1186/s12876-019-1040-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
154 Kojima S, Kuo TF, Tatsukawa H, Hirose S. Induction of cross-linking and silencing of Sp1 by transglutaminase during liver injury in ASH and NASH via different ER stress pathways. Dig Dis 2010;28:715-21. [PMID: 21525755 DOI: 10.1159/000324278] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
155 Le Naour F, Bralet MP, Debois D, Sandt C, Guettier C, Dumas P, Brunelle A, Laprévote O. Chemical imaging on liver steatosis using synchrotron infrared and ToF-SIMS microspectroscopies. PLoS One 2009;4:e7408. [PMID: 19823674 DOI: 10.1371/journal.pone.0007408] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
156 Sugiishi A, Kimura M, Kamiya R, Ueki S, Yoneya M, Saito Y, Saito H. Derangement of ghrelin secretion after long-term high-fat diet feeding in rats. Hepatol Res 2013;43:1105-14. [PMID: 23374505 DOI: 10.1111/hepr.12062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
157 Moscatiello S, Di Luzio R, Bugianesi E, Suppini A, Hickman IJ, Di Domizio S, Dalle Grave R, Marchesini G. Cognitive-Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Score-Adjusted Observational Study. Obesity 2011;19:763-70. [DOI: 10.1038/oby.2010.254] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
158 Pavlik L, Regev A, Ardayfio PA, Chalasani NP. Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Drug Saf 2019;42:701-11. [PMID: 30762163 DOI: 10.1007/s40264-018-00790-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
159 Duric M, Sivanesan S, Bakovic M. Phosphatidylcholine functional foods and nutraceuticals: A potential approach to prevent non-alcoholic fatty liver disease. Eur J Lipid Sci Technol 2012;114:389-98. [DOI: 10.1002/ejlt.201100350] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
160 Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? Journal of Hepatology 2011;54:1020-9. [DOI: 10.1016/j.jhep.2010.11.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 9.2] [Reference Citation Analysis]
161 Decker RD, Ghiraldi EM, Weiss AH, Gaughan JP, Friedlander JI. Nonalcoholic Fatty Liver Disease Is an Independent Risk Factor for Nephrolithiasis in Women: Findings from NHANES III. J Endourol 2020;34:1258-62. [PMID: 32571100 DOI: 10.1089/end.2020.0486] [Reference Citation Analysis]
162 Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503-508. [PMID: 19766548 DOI: 10.1016/j.dld.2009.08.002] [Cited by in Crossref: 386] [Cited by in F6Publishing: 373] [Article Influence: 29.7] [Reference Citation Analysis]
163 Debois D, Bralet MP, Le Naour F, Brunelle A, Laprévote O. In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF-SIMS imaging. Anal Chem. 2009;81:2823-2831. [PMID: 19296690 DOI: 10.1021/ac900045m] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 9.6] [Reference Citation Analysis]
164 Das K, Chowdhury A. Lean NASH: distinctiveness and clinical implication. Hepatol Int 2013;7 Suppl 2:806-13. [PMID: 26202295 DOI: 10.1007/s12072-013-9477-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
165 Lee J, Ha J, Jo K, Lim DJ, Lee JM, Chang SA, Kang MI, Cha BY, Kim MH. Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015. Sci Rep. 2018;8:15145. [PMID: 30310098 DOI: 10.1038/s41598-018-32245-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
166 Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 2011;34:544-51. [PMID: 21427524 DOI: 10.3275/7614] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
167 Yu J, Chu ES, Wang R, Wang S, Wu CW, Wong VW, Chan HL, Farrell GC, Sung JJ. Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology. 2010;138:694-704, 704.e1. [PMID: 19818781 DOI: 10.1053/j.gastro.2009.09.058] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
168 Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH; the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG). Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol 2019;25:1-11. [PMID: 30086613 DOI: 10.3350/cmh.2018.0037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
169 Yang SJ, Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism. 2014;63:693-701. [PMID: 24629563 DOI: 10.1016/j.metabol.2014.02.003] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 10.1] [Reference Citation Analysis]
170 Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A, Solioz M, Tilg H, Patsch W, Weiss G. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol. 2010;105:1978-1985. [PMID: 20407430 DOI: 10.1038/ajg.2010.170] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 8.7] [Reference Citation Analysis]
171 Vares G, Wang B, Ishii-Ohba H, Nenoi M, Nakajima T. Diet-induced obesity modulates epigenetic responses to ionizing radiation in mice. PLoS One 2014;9:e106277. [PMID: 25171162 DOI: 10.1371/journal.pone.0106277] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
172 de Lédinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, Le Bail B, Choi PC, Chermak F, Yiu KK, Merrouche W, Chan HL. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol 2012;56:833-9. [PMID: 22173167 DOI: 10.1016/j.jhep.2011.10.017] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 15.1] [Reference Citation Analysis]
173 Arase Y, Kawamura Y, Seko Y, Kobayashi M, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res. 2013;43:1163-1168. [PMID: 23489256 DOI: 10.1111/hepr.12077] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
174 Okada K, Warabi E, Sugimoto H, Horie M, Tokushige K, Ueda T, Harada N, Taguchi K, Hashimoto E, Itoh K. Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. J Gastroenterol. 2012;47:924-935. [PMID: 22367278 DOI: 10.1007/s00535-012-0552-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 4.7] [Reference Citation Analysis]
175 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse AW, Mann O, Kluwe J. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond) 2021. [PMID: 34168277 DOI: 10.1038/s41366-021-00881-8] [Reference Citation Analysis]
176 Ma H, You G, Cui F, Chen L, Yang X, Chen L, Lu H, Zhang W. Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD. Annals of Hepatology 2015;14:108-17. [DOI: 10.1016/s1665-2681(19)30807-5] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
177 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785 [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
178 Graeter T, Niedermayer PC, Mason RA, Oeztuerk S, Haenle MM, Koenig W, Boehm BO, Kratzer W. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes. 2015;8:640. [PMID: 26530296 DOI: 10.1186/s13104-015-1645-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
179 Jin X, Chen YP, Kong M, Zheng L, Yang YD, Li YM. Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. J Gastroenterol Hepatol. 2012;27:331-340. [PMID: 21793903 DOI: 10.1111/j.1440-1746.2011.06864.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
180 Sun W, Liu P, Wang T, Wang X, Zheng W, Li J. Baicalein reduces hepatic fat accumulation by activating AMPK in oleic acid-induced HepG2 cells and high-fat diet-induced non-insulin-resistant mice. Food Funct 2020;11:711-21. [DOI: 10.1039/c9fo02237f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
181 Labrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh K, Hamid SS, Isakov V, Lizarzabal M, Peñaranda MM, Ramos JF, Sarin S, Stimac D, Thomson AB, Umar M, Krabshuis J, Lemair A. World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology 2014;48:467-73. [DOI: 10.1097/mcg.0000000000000116] [Cited by in Crossref: 193] [Cited by in F6Publishing: 113] [Article Influence: 24.1] [Reference Citation Analysis]
182 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 7.3] [Reference Citation Analysis]
183 Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, Akuta N, Ito K, Kawanaka M, Hiramatsu A, Sakamoto M, Harada K, Goto Y, Nakayama T, Kumada H, Okanoue T. Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. Hepatol Res. 2018;48:1099-1107. [PMID: 29974624 DOI: 10.1111/hepr.13226] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
184 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
185 Sirek AS, Liu L, Naples M, Adeli K, Ng DS, Jin T. Insulin stimulates the expression of carbohydrate response element binding protein (ChREBP) by attenuating the repressive effect of Pit-1, Oct-1/Oct-2, and Unc-86 homeodomain protein octamer transcription factor-1. Endocrinology 2009;150:3483-92. [PMID: 19359385 DOI: 10.1210/en.2008-1702] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
186 Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol. 2011;26 Suppl 1:96-101. [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
187 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
188 Chatterjee A, Basu A, Chowdhury A, Das K, Sarkar-Roy N, Majumder PP, Basu P. Comparative analyses of genetic risk prediction methods reveal extreme diversity of genetic predisposition to nonalcoholic fatty liver disease (NAFLD) among ethnic populations of India. J Genet 2015;94:105-13. [PMID: 25846882 DOI: 10.1007/s12041-015-0494-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
189 Maruyama H, Kobayashi K, Kiyono S, Yokosuka O. Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis. Int J Med Sci 2017;14:240-5. [PMID: 28367084 DOI: 10.7150/ijms.17738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
190 Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009;86:513-28. [PMID: 19542050 DOI: 10.1189/JLB.0309135] [Cited by in Crossref: 242] [Cited by in F6Publishing: 157] [Article Influence: 18.6] [Reference Citation Analysis]
191 Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One 2014;9:e113651. [PMID: 25470250 DOI: 10.1371/journal.pone.0113651] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 19.0] [Reference Citation Analysis]
192 Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl). 2016;94:613-627. [PMID: 27094811 DOI: 10.1007/s00109-016-1408-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 10.8] [Reference Citation Analysis]
193 Lafdil F, Miller AM, Ki SH, Gao B. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol. 2010;7:250-254. [PMID: 20305686 DOI: 10.1038/cmi.2010.5] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 7.2] [Reference Citation Analysis]
194 Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Nordlinger B. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145:362-371. [PMID: 19303984 DOI: 10.1016/j.surg.2008.12.002] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 7.0] [Reference Citation Analysis]
195 Ye P, Liu J, Xu W, Liu D, Ding X, Le S, Zhang H, Chen S, Chen M, Xia J. Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression. Hepatology 2019;69:1946-64. [PMID: 30582764 DOI: 10.1002/hep.30485] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
196 Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen H. Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:719-26. [DOI: 10.1097/mcg.0b013e3182819a89] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
197 Chou M, Chang R, Hung Y, Chen Y, Chiu C. Antrodia camphorata ameliorates high-fat-diet induced hepatic steatosis via improving lipid metabolism and antioxidative status. Journal of Functional Foods 2013;5:1317-25. [DOI: 10.1016/j.jff.2013.04.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
198 de Lédinghen V, Hiriart J, Vergniol J, Merrouche W, Bedossa P, Paradis V. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy. Dig Dis Sci 2017;62:2569-77. [DOI: 10.1007/s10620-017-4638-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
199 Mirrakhimov AE, Polotsky VY. Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target? Front Neurol. 2012;3:149. [PMID: 23087670 DOI: 10.3389/fneur.2012.00149] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
200 de Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, Merrouche W, Foucher J, Brigitte le B. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60:1026-1031. [PMID: 24378529 DOI: 10.1016/j.jhep.2013.12.018] [Cited by in Crossref: 210] [Cited by in F6Publishing: 178] [Article Influence: 23.3] [Reference Citation Analysis]
201 Lucas C, Lucas G, Lucas N, Krzowska-Firych J, Tomasiewicz K. A systematic review of the present and future of non-alcoholic fatty liver disease. Clin Exp Hepatol 2018;4:165-74. [PMID: 30324141 DOI: 10.5114/ceh.2018.78120] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
202 Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, Lafdil F, Gao B. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology. 2011;54:846-856. [PMID: 21725996 DOI: 10.1002/hep.24517] [Cited by in Crossref: 106] [Cited by in F6Publishing: 105] [Article Influence: 10.6] [Reference Citation Analysis]
203 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
204 Maruyama H, Kondo T, Sekimoto T, Takahashi M, Fujiwara K, Imazeki F, Yokosuka O. Retrograde detection of the intrahepatic portal vein in primary biliary cirrhosis: is sinusoidal blockage the underlying pathophysiology? Eur J Gastroenterol Hepatol. 2015;27:321-327. [PMID: 25563140 DOI: 10.1097/meg.0000000000000268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
205 Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, Amor IB, Staccini-Myx A, Saint-Paul MC, Berthier F, Huet PM, Le Marchand-Brustel Y, Gugenheim J, Gual P, Tran A. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010;32:1315-1322. [PMID: 21050233 DOI: 10.1111/j.1365-2036.2010.04480.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 7.7] [Reference Citation Analysis]
206 de Lédinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, Chermak F, Choi PC, Foucher J, Chan CK, Merrouche W, Chim AM, Le Bail B, Wong VW. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31:848-55. [PMID: 26514665 DOI: 10.1111/jgh.13219] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 14.5] [Reference Citation Analysis]
207 Shpirer I, Copel L, Broide E, Elizur A. Continuous positive airway pressure improves sleep apnea associated fatty liver. Lung. 2010;188:301-307. [PMID: 20066542 DOI: 10.1007/s00408-009-9219-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
208 Kawamura Y, Ikeda K, Arase Y, Sorin Y, Fukushima T, Kunimoto H, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int. 2015;9:269-277. [PMID: 25788193 DOI: 10.1007/s12072-014-9605-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
209 Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7:456-465. [PMID: 21556019 DOI: 10.1038/nrendo.2011.72] [Cited by in Crossref: 200] [Cited by in F6Publishing: 190] [Article Influence: 18.2] [Reference Citation Analysis]
210 Kuo TF, Tatsukawa H, Matsuura T, Nagatsuma K, Hirose S, Kojima S. Free fatty acids induce transglutaminase 2-dependent apoptosis in hepatocytes via ER stress-stimulated PERK pathways. J Cell Physiol. 2012;227:1130-1137. [PMID: 21567402 DOI: 10.1002/jcp.22833] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
211 Chen L, Huang P, Chien C, Lin C, Chien R. A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. Journal of the Formosan Medical Association 2020;119:173-81. [DOI: 10.1016/j.jfma.2019.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
212 Esteghamati A, Noshad S, Khalilzadeh O, Khalili M, Zandieh A, Nakhjavani M. Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2011;9:111-7. [PMID: 21091060 DOI: 10.1089/met.2010.0066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
213 Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M. Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat. 2012;2012:947575. [PMID: 23227320 DOI: 10.1155/2012/947575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
214 Konopelska S, Kienitz T, Quinkler M. Downregulation of hepatic glucose-6-phosphatase-α in patients with hepatic steatosis. Obesity (Silver Spring) 2011;19:2322-6. [PMID: 21593806 DOI: 10.1038/oby.2011.118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
215 Chang Y, Chou C, Chiu C, Yang K, Lin Y, Weng W, Chen Y. Preventive Effects of Taurine on Development of Hepatic Steatosis Induced by a High-Fat/Cholesterol Dietary Habit. J Agric Food Chem 2011;59:450-7. [DOI: 10.1021/jf103167u] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 6.2] [Reference Citation Analysis]
216 Rey JW, Noetel A, Hardt A, Canbay A, Alakus H, Hausen AZ, Dienes HP, Drebber U, Odenthal M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases. World J Gastroenterol 2010; 16(46): 5830-5837 [PMID: 21155004 DOI: 10.3748/wjg.v16.i46.5830] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
217 Patinkin ZW, Feinn R, Santos M. Metabolic Consequences of Obstructive Sleep Apnea in Adolescents with Obesity: A Systematic Literature Review and Meta-Analysis. Child Obes 2017;13:102-10. [PMID: 27936906 DOI: 10.1089/chi.2016.0248] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
218 Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H, Sorin Y, Fujiyama S, Sezaki H, Hosaka T. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int. 2016;10:647-656. [PMID: 27074850 DOI: 10.1007/s12072-016-9729-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
219 Segers FM, Verdam FJ, de Jonge C, Boonen B, Driessen A, Shiri-Sverdlov R, Bouvy ND, Greve JW, Buurman WA, Rensen SS. Complement alternative pathway activation in human nonalcoholic steatohepatitis. PLoS One 2014;9:e110053. [PMID: 25299043 DOI: 10.1371/journal.pone.0110053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
220 Xu G, Wang YM, Ying MM, Chen SD, Li ZR, Ma HL, Zheng MH, Wu J, Ding C. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis. Clin Mol Hepatol 2021;27:329-45. [PMID: 33465844 DOI: 10.3350/cmh.2020.0261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Akuta N, Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Ikeda K, Kumada H. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. Gut Liver. 2016;10:437-445. [PMID: 26610348 DOI: 10.5009/gnl15163] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
222 Farrell G, Fan J. Prevention of Hepatocellular Carcinoma. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 36-61. [DOI: 10.3109/9780203092880-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
223 Di Q. Risk factors for type 2 diabetes accompanying nonalcoholic fatty liver: an analysis of 58 cases. Shijie Huaren Xiaohua Zazhi 2010; 18(14): 1497-1500 [DOI: 10.11569/wcjd.v18.i14.1497] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
224 Paris T, George ES, Roberts SK, Tierney AC. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review. European Journal of Gastroenterology & Hepatology 2017;29:867-78. [DOI: 10.1097/meg.0000000000000890] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
225 Maruyama H, Kondo T, Sekimoto T, Yokosuka O. Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension. Medicine (Baltimore) 2015;94:e1056. [PMID: 26131820 DOI: 10.1097/MD.0000000000001056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
226 Le Naour F, Guettier C, Brunelle A, Laprévote O, Dumas P. [Synchrotron SOLEIL radiation reveals discrete biochemical changes in human steatosis]. Med Sci (Paris) 2009;25:987-90. [PMID: 19951680 DOI: 10.1051/medsci/20092511987] [Reference Citation Analysis]
227 Dostbil Z, Varoğlu E, Serdengeçti M, Kaya B, Önder H, Sari O. Evaluation of hepatic metabolic activity in non-alcoholic fatty livers on 18FDG PET/CT. Revista Española de Medicina Nuclear e Imagen Molecular 2013;32:156-61. [DOI: 10.1016/j.remn.2012.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
228 Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930-1940. [PMID: 23696515 DOI: 10.1002/hep.26455] [Cited by in Crossref: 286] [Cited by in F6Publishing: 257] [Article Influence: 31.8] [Reference Citation Analysis]
229 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
230 Ulukaya E, Yilmaz Y, Moshkovskii S, Karpova M, Pyatnitskiy M, Atug O, Dolar E. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol. 2009;44:1471-1476. [PMID: 19883279 DOI: 10.3109/00365520903353379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
231 Dean JT, Tran L, Beaven S, Tontonoz P, Reue K, Dipple KM, Liao JC. Resistance to diet-induced obesity in mice with synthetic glyoxylate shunt. Cell Metab 2009;9:525-36. [PMID: 19490907 DOI: 10.1016/j.cmet.2009.04.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
232 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]